Gossamer Bio Reports Worsening Q1 Loss, Reiterates Going Concern Amidst Nasdaq Delisting Threat & Lawsuit
GOSS is trading near its 52-week low of $0.314 (6.0% above the low) on light trading volume (0.3× avg).
Summary
Gossamer Bio's Q1 report highlights severe financial distress with increased losses, dwindling cash, a reiterated going concern warning, a Nasdaq delisting notice, and a new class-action lawsuit, alongside a significant stock option repricing.
Key Events · Earnings and Guidance · GOSS
-
Worsening Financial Performance
Net loss for Q1 2026 increased to $46.7 million, up from $36.6 million in Q1 2025. Cash, cash equivalents, and marketable securities decreased to $99.2 million as of March 31, 2026, from $136.9 million at December 31, 2025.
-
Reiterated Going Concern Warning
The company explicitly states that existing cash and cash equivalents are insufficient to fund operations for at least one year, projecting a cash runway only into the first quarter of 2027.
-
Nasdaq Delisting Notice
Gossamer Bio received a notice from Nasdaq on April 9, 2026, for failing to meet the minimum $1.00 bid price requirement, initiating delisting procedures.
-
Class Action Lawsuit Filed
A putative class action lawsuit was filed on March 31, 2026, alleging false and misleading statements and failure to disclose material adverse facts between June 2025 and February 2026.
Analysis · GOSS · Life Sciences
Gossamer Bio's first-quarter report reveals a deepening financial crisis, with net losses increasing to $46.7 million and cash, cash equivalents, and marketable securities declining to $99.2 million, down from $136.9 million at year-end 2025. The company explicitly reiterates its 'going concern' warning, projecting a cash runway only into Q1 2027. This dire financial situation is compounded by a Nasdaq delisting notice received in April 2026 for failing to meet the minimum bid price, and a class-action lawsuit filed in March 2026 alleging securities fraud. The company also detailed a significant stock option repricing in March 2026 for 48.7 million options to $0.45 per share, a clear sign of distress and an attempt to retain employees amidst the challenges.
At the time of this filing, GOSS was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.31 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.